Although white coat hypertension has been widely studied in the last years, its risk profile is not yet completely clear. The aim of this study was to evaluate circulating homocysteine levels, an emerging cardiovascular risk factor, in subjects with white coat and sustained hypertension. We selected 31 sustained hypertensive subjects, 31 white coat hypertensive subjects and 31 normotensive subjects matched for age, gender, body mass index and occupation. Women were also matched for menopausal status. Subjects with smoking habit, dyslipidaemia and diabetes mellitus were excluded from the study. White coat hypertension was defined as clinical hypertension and daytime ambulatory blood pressure o135/85 mmHg. Blood samples were drawn after a fasting period of 12 h for routine laboratory tests and homocysteine determination. Homocysteine levels were evaluated by fluorescence polarization immunoassay. Creatinine, glucose, cholesterol and triglycerides were not different among the groups. White coat hypertensive subjects had significantly lower homocysteine levels than sustained hypertensive patients (8.2 7 2.0 vs 12.6 7 3.9 lmol/l, P ¼ 0.0003). No significant difference was observed between white coat hypertensive and normotensive subjects regarding this parameter (8.2 7 2.0 vs 7.6 7 1.9 lmol/l, P ¼ 0.9). In conclusion, our data show that middle-aged white coat hypertensive subjects without other cardiovascular risk factors have lower circulating homocysteine levels than sustained hypertensive patients suggesting that they are at lower cardiovascular risk.
Introduction
White coat hypertension 1,2 (also known as isolated clinic hypertension), that is, high clinic blood pressure (BP) but 'normal' ambulatory BP, has been widely studied in the last years. At present, however, it remains a matter of controversy because its risk profile and clinical relevance are not yet completely clear. Some studies have shown that white coat hypertension is not associated with target organ damage, 3-9 clustering of risk factors (eg hypercholesterolaemia, low high-density lipoprotein cholesterol, insulin resistance), [7] [8] [9] [10] [11] [12] [13] [14] and adverse cardiovascular outcome. [15] [16] [17] On the other hand, different results have been obtained in other reports. [18] [19] [20] [21] [22] [23] [24] [25] [26] Various studies have suggested that only about one-half to two-thirds of the variation in the anatomic extent of atherosclerosis and risk for atherosclerotic vascular disease can be explained by classic risk factors. 27, 28 Therefore, new risk factors have been investigated. Among these, homocysteine is emerging as an independent risk factor for vascular disease. Indeed, various studies have demonstrated an association between homocysteine levels and cerebral, coronary and peripheral vascular disease in both men and women. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] This association is usually consistent, strong, dose-related and biologically plausibile. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Some mechanisms have been suggested to explain the increased vascular risk associated with higher homocysteine levels. 40, 42, 43 One of this is endothelial dysfunction in humans. 40, 42, 43 This mechanism could also contribute to the genesis or maintenance of hypertension. Little is known, at present, about the association between homocysteine levels and BP in uncomplicated hypertensive subjects. [44] [45] [46] Moreover, to the best of our knowledge, no study has evaluated circulating homocysteine levels in white coat hypertension.
The present study was designed to evaluate circulating homocysteine levels in subjects with white coat hypertension compared with subjects with normotension and those with sustained hypertension in a cross-sectional study.
Methods

Subjects
We selected 31 normotensive, 31 white coat hypertensive and 31 sustained hypertensive subjects matched for age, gender, body mass index and occupation. Women were also matched for menopausal status. Exclusion criteria for entry into the study were antihypertensive (present or past) or other drug use (including vitamin supplements), alcohol and/or coffee abuse, smoking habit, dyslipidaemia, diabetes mellitus, obesity, secondary hypertension, renal failure, heart failure, cerebrovascular disease, ischaemic heart disease, peripheral vascular disease and heavy physical activity. Study population came from the same geographical area (Chieti, Abruzzo, Italy) and had a similar dietary pattern. The study was in accordance with the Second Declaration of Helsinki and was approved by the institutional committee on human research. All subjects gave informed consent.
Office BP measurements
Clinic systolic and diastolic BP recordings were performed according to the standard technique with the subject in the supine position. Measurements were performed in triplicate, and the average value was used as the BP for the visit. Clinic hypertension was defined as systolic BPX140 mmHg and/or diastolic BPX90 mmHg at each of three visits. Clinic normotension was defined as BPo140/90 mmHg.
Ambulatory BP monitoring
Ambulatory BP monitoring was performed with a portable noninvasive recorder (SpaceLabs 90207, Redmond, WA, USA) on a day of typical activity. Technical aspects have been previously reported. 8 Ambulatory BP readings were obtained at 15-min intervals from 6 am to midnight, and at 30-min intervals from midnight to 6 am. The following ambulatory BP parameters were evaluated: average daytime (awake period), night time (asleep period) and 24-h systolic and diastolic BP. Awake and asleep periods were calculated from diary times. Recordings were automatically edited. 8 Subjects included in the study had recordings of good technical quality. White coat hypertension was defined as clinic hypertension and daytime BPo135/85 mmHg. 47 
Laboratory procedures
Blood samples were drawn after a fasting period of 12 h. Glucose, creatinine, total cholesterol, triglycerides and high-density lipoprotein cholesterol were determined by standard methods. Low-density lipoprotein (LDL) cholesterol was calculated with Friedewald's formula. Blood samples for homocysteine determination were centrifuged immediately at 1000 Â g for 10 min and the supernatant was collected and frozen at -201C until assayed. Homocysteine was measured by fluorescence polarization immunoassay with the IMX system (Abbott Diagnostics, IL, USA) as previously described. 48 The assay coefficient of variation ranges from 3.7 to 5.3% when measuring samples between 5 and 25 mmol/l.
Statistical analysis
Data are expressed as mean 7 s.d. Differences of homocysteine levels of 3-5 mmol/l, also in the 'normal' range, have been reported to be associated with increased risk. Based on a mean difference of 4 mmol/l and the s.d. obtained by our preliminary data, for a ¼ 0.05 (between each group) and power ¼ 80%, a sample size per group 425 subjects was needed to detect an actual difference. Groups were compared with one-way ANOVA followed by Scheffè's test for multiple comparisons or with the Kruskal-Wallis test followed by the Mann-Whitney U-test for multiple comparisons, and w 2 test or Fisher's exact test, where appropriate. 49 Spearman's correlation was used to evaluate the association between homocysteine levels and clinic and ambulatory BP. Analyses were made with the use of SYSTAT 10 package. Statistical significance was defined as Po0.05.
Results
The main characteristics of study population are reported in Table 1 . Age, gender distribution and body mass index did not differ among the groups by selection.
Clinic BP was significantly higher in sustained hypertensives and white coat hypertensives than in normotensives; it was also higher in sustained hypertensives than in white coat hypertensives. Ambulatory BP was significantly higher in sustained hypertensives than in white coat hypertensives and normotensives, and was similar between white coat hypertensives and normotensives.
Alcohol and coffee intake, and physical activity were not different among the groups (data not shown).
Laboratory parameters were not different among the study groups as a result of the selection process (Table 2) .
Homocysteine levels in the study population are shown in Figure 1 . Homocysteine levels were significantly higher in sustained hypertensives than in white coat hypertensives and normotensives; there was no significant difference between white coat hypertensives and normotensives.
Using 15 mmol/l as the upper limit of normal, the percentage of subjects with homocysteine concentration above this value was significantly higher in the sustained hypertensive group (22.6%, seven patients) than in the white coat and normotensive groups (0%), (Po0.05). Using the 95th percentile (11 mmol/l) of homocysteine distribution in our selected normotensive population as the upper limit of normal, the percentage of subjects with homocysteine concentration above this threshold was significantly higher in the sustained hypertensive group (68%, 21 patients) than in the white coat hypertensive group (two subjects) and normotensive group (one subject) (Po0.05).
In this selected study population as a whole, the correlation between homocysteine levels and clinic systolic and diastolic BP did not attain statistical significance (r ¼ 0.20, P ¼ 0.06 and r ¼ 0.19, P ¼ 0.07, respectively); on the contrary, there was a significant association between homocysteine levels and 24-h systolic and diastolic BP (r ¼ 0.47, P ¼ 0.0001 and r ¼ 0.45, P ¼ 0.0001, respectively). When the groups were analyzed separately, there was no significant correlation between homocysteine levels and clinic or 24-h BP both in the normotensive and in the white coat hypertensive groups; in the sustained hypertensive group, there was no significant correlation between homocysteine levels and clinic BP but there was a significant correlation between homocysteine level and 24-h systolic and diastolic BP (r ¼ 0.35, P ¼ 0.04 and r ¼ 0.34, P ¼ 0.045, respectively).
Discussion
White coat hypertension has been widely studied in the last years but its risk profile is not yet completely clear. Various studies performed in these subjects and evaluating organ damage and classic cardiovascular risk factors obtained conflicting result, although all available prospective studies have reported a lower cardiovascular morbidity and mortality in white coat hypertension than in sustained hypertension. [15] [16] [17] This is the first study, to our knowledge, to evaluate circulating homocysteine levels, an emerging cardiovascular risk factor, in white coat hypertension. In this selected population, we have found lower circulating homocysteine levels in white coat hypertensive subjects in comparison with sustained hypertensive patients, whereas no significant difference was found between white coat and normotensive subjects. The definition of increased homocysteine levels is not yet standardized and substantial differences exist in the 'normal' reference values used in the literature. At first it was proposed to use the threshold of 15 mmol/l to define high homocysteine levels in the study populations. 40 However, various studies have shown a graded relation between homocysteine levels and cardiovascular risk with no clear threshold levels. [29] [30] [31] [32] [33] [35] [36] [37] [38] [39] [40] [41] These studies reported an increased risk in many individuals categorized as falling within the 'normal' range using the cutoff level of 15 mmol/l, particularly in those with homocysteine levels higher than 10 mmol/l. [29] [30] [31] [32] [33] [35] [36] [37] [38] [39] [40] [41] For example, Malinow et al 29 have reported an increased risk of intima-media thickening in subjects with homocysteine levels higher than 10.5 mmol/l and Selhub et al 30 have reported a higher risk of extracranial carotid artery stenosis in subjects with homocysteine concentrations above 11.3 mmol/l. In the same context, Perry et al 31 have reported an about two-fold increase in the risk of stroke in middle-aged British men with homocysteine concentrations higher than 12.5 mmol/l and Giles et al 32 have reported an increased risk of nonfatal stroke in US adults with homocysteine levels above 12 mmol/l. It has also been reported an increased risk of coronary artery disease in subjects with homocysteine levels in the 'normal' range, particularly in those with homocysteine values ranging from 10 to 15 mmol/l.
35,39
Moreover, Graham et al 37 have reported, in the European Concerted Action Project, that an increased homocysteine level (412 mmol/l) confers an independent risk of all categories of atherosclerotic vascular disease in both men and women, and that it powerfully increases the risk associated with hypertension.
Taken together, the aforementioned studies suggest that homocysteine levels above 10 mmol/l may be considered elevated and associated with increased risk. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] The vast majority of our subjects in the sustained hypertensive group, but not in the white coat hypertensive one, had homocysteine levels indicating an increased vascular risk. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] The present findings confirm the tendency to the clustering of cardiovascular risk factors in the sustained hypertensive population, but not in the white coat hypertensive one, and suggest that white coat hypertensive subjects are at lower cardiovascular risk than those with sustained hypertension. These results could contribute to explain the lower reported cardiovascular morbidity and mortality in white coat hypertensive subjects in comparison with sustained hypertensive patients. [15] [16] [17] Little is known about the relation between BP and homocysteine levels in uncomplicated hypertensive patients. [44] [45] [46] In our clinic hypertensive population, only patients with both clinic and ambulatory hypertension (sustained hypertension), but not those with only clinic hypertension (white coat hypertension), had higher homocysteine levels than normotensive subjects. Moreover, we did not find a significant correlation between homocysteine levels and clinic BP, in accordance with Lip et al, 50 but we found a significant correlation between homocysteine levels and 24-h BP, in accordance with Tsioufis et al. 51 Whether this finding represents an association because of the clustering of cardiovascular risk factors in the sustained hypertensive population or is related to the influence of homocysteine on ambulatory BP is at present unknown. Further studies are needed to evaluate whether homocysteine plays a role in the pathophysiology of hypertension.
Some mechanisms have been proposed to explain the increased vascular risk induced by higher homocysteine levels. 40, 42, 43 Particularly, it has been suggested that elevated homocysteine levels may be one of the factors inducing increased oxidative stress and endothelial dysfunction. 40, 42, 43 In this context, we have recently shown increased oxidative stress 11 and endothelial dysfunction 52 in sustained hypertensive patients but not in white coat hypertensive subjects.
The present study has some limitations. First, since we excluded subjects with smoking habit, dislipidaemia and diabetes mellitus our results cannot be extrapolated to all white coat hypertensive subjects. Homocysteine levels in white coat hypertensive subjects with additional cardiovascular risk factors have to be determined. Second, since we studied only Caucasian subjects our conclusions may not be extended to other racial groups. Third, since we did not evaluate genotypes of enzymes involved in homocysteine metabolism and folic acid, vitamin B 6 and vitamin B 12 status, it is unclear whether the present findings are related to genetic or nutritional factors. However, regardless of the mechanism, higher homocysteine levels represent a risk factor for vascular disease. Thus, this limitation does not lessen the clinical relevance of our findings.
In conclusion, our data show that middle-aged white coat hypertensive subjects without other cardiovascular risk factors have lower circulating homocysteine levels than sustained hypertensive patients suggesting that they are at lower cardiovascular risk. 
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